



08-25-03 1702 Rec'd PCT/PTO 22 AUG 2003
JP 10

EXPRESS MAIL CERTIFICATE

DATE 8/22/03 LABEL No. EV 306629605US

I HEREBY CERTIFY THAT, ON THE DATE INDICATED ABOVE
THIS PAPER OR FEE WAS DEPOSITED WITH THE U.S. POSTAL SERVICE
& THAT IT WAS ADDRESSED FOR DELIVERY TO THE COMMISSIONER
FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 BY "EXPRESS
MAIL POST OFFICE TO ADDRESSEE" SERVICE.

S. Stantini S. Stantini
NAME (PRINT) SIGNATURE

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Customer No.: **07278**

Docket No.: 4280/0M988

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sai L. SU ET AL.

Serial No: 10/009,508

Group Art Unit: TBA

Filed: 11/6/2001

Examiner: TBA

Confirmation No.: 5007

For: METHODS FOR THE DIAGNOSIS AND TREATMENT OF METASTATIC PROS-
TATE TUMORS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of
PTO/SB/08A and copies¹ of the documents listed thereon. These documents contain

¹ If a listed document is not in the English language and an English translation is readily available, such translation is also enclosed and attached to the copy of the document. If a translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then the English equivalent patent is also listed on the enclosed form along with the corresponding

information which the Examiner should consider during examination of the present application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached PTO/SB/08A) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing PTO/SB/08A next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.


The undersigned is also enclosing herewith an English copy of a Supplementary Partial European Search Report issued March 20, 2003 in the European counterpart of the present patent application, in which the presently disclosed references were cited. Since the Search Report is in English, it is believed that the applicants in the above-identified patent application have now met the "concise explanation" requirement of 35 C.F.R. 1.98.

The present Supplemental Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

foreign language patent and a connecting arrow indicates the relationship between them. If no such English language equivalent is cited, then none is known to the undersigned.

Respectfully submitted,



Anna Löqvist, Ph.D.

Limited Recognition Under
37 C.F.R. §10.9(b) (see enclosure)
Representative for Applicant(s)

DARBY & DARBY P.C.
P.O. Box 5257
New York, NY 10150-5257
(212) 527-7700



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/009,508
				Filing Date	August 15, 2002
				First Named Inventor	Sai L. Su et al.
				Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	1	Attorney Docket Number	4280/0M988

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	1	WO 95/27061A	10/12/95	Bennett et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2	SU S L ET AL., Expression of vascular endothelial growth factor (VEGF), VEGF-C, and their receptors in prostate cancer (CaP), Proceedings of the American Association for Cancer Research Annual, vol. 40, March 1999 (1999-03), page 614	
	3	ISRAELI R S ET AL., Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cell: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays, Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 54, 15 December 1994, pages 6306-6310	
	4	MURPHY G P ET AL., Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen, Cancer, American Cancer Society, Philadelphia, PA, 1 December 1998, vol. 83, no. 11, pages 2259-2269	
	5	TSURUSAKI T ET AL., Vascular endothelial growth factor-c expression in human prostatic carcinoma and its relationship to lymph node metastasis, British Journal of Cancer, London, GB, April 1999, vol. 80, no 1/2, pages 309-313	
	6	Database EMBL, 1 May 1993, retrieved from EBI, accession no. X69878	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--